

# Andrew John Mallett

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6583701/publications.pdf>

Version: 2024-02-01

79  
papers

1,479  
citations

361296

20  
h-index

377752

34  
g-index

84  
all docs

84  
docs citations

84  
times ranked

2284  
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient-iPSC-Derived Kidney Organoids Show Functional Validation of a Ciliopathic Renal Phenotype and Reveal Underlying Pathogenetic Mechanisms. <i>American Journal of Human Genetics</i> , 2018, 102, 816-831.	2.6	157
2	Genome-wide association study of medication-use and associated disease in the UK Biobank. <i>Nature Communications</i> , 2019, 10, 1891.	5.8	140
3	Ciliopathies and the Kidney: A Review. <i>American Journal of Kidney Diseases</i> , 2021, 77, 410-419.	2.1	116
4	Treatment and long-term outcome in primary distal renal tubular acidosis. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 981-991.	0.4	75
5	Massively parallel sequencing and targeted exomes in familial kidney disease can diagnose underlying genetic disorders. <i>Kidney International</i> , 2017, 92, 1493-1506.	2.6	74
6	Clinical impact of genomic testing in patients with suspected monogenic kidney disease. <i>Genetics in Medicine</i> , 2021, 23, 183-191.	1.1	70
7	The prevalence and epidemiology of genetic renal disease amongst adults with chronic kidney disease in Australia. <i>Orphanet Journal of Rare Diseases</i> , 2014, 9, 98.	1.2	54
8	Mutations in mitochondrial DNA causing tubulointerstitial kidney disease. <i>PLoS Genetics</i> , 2017, 13, e1006620.	1.5	52
9	Genetics in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2022, 101, 1126-1141.	2.6	46
10	End-stage kidney disease due to Alport syndrome: outcomes in 296 consecutive Australia and New Zealand Dialysis and Transplant Registry cases. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 2277-2286.	0.4	40
11	Clinical spectrum, prognosis and estimated prevalence of DNAJB11-kidney disease. <i>Kidney International</i> , 2020, 98, 476-487.	2.6	38
12	Identifying and integrating consumer perspectives in clinical practice guidelines on autosomal dominant polycystic kidney disease. <i>Nephrology</i> , 2016, 21, 122-132.	0.7	33
13	A multidisciplinary renal genetics clinic improves patient diagnosis. <i>Medical Journal of Australia</i> , 2016, 204, 58-59.	0.8	31
14	Attitudes and Practices of Australian Nephrologists Toward Implementation of Clinical Genomics. <i>Kidney International Reports</i> , 2021, 6, 272-283.	0.4	28
15	A mutation affecting laminin alpha 5 polymerisation gives rise to a syndromic developmental disorder. <i>Development (Cambridge)</i> , 2020, 147, .	1.2	28
16	End-Stage Kidney Disease Due to Fibrillary Glomerulonephritis and Immunotactoid Glomerulopathy - Outcomes in 66 Consecutive ANZDATA Registry Cases. <i>American Journal of Nephrology</i> , 2015, 42, 177-184.	1.4	26
17	KHA-CARI guideline recommendations for the diagnosis and management of autosomal dominant polycystic kidney disease. <i>Nephrology</i> , 2016, 21, 705-716.	0.7	26
18	Gitelman-Like Syndrome Caused by Pathogenic Variants in mtDNA. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 305-325.	3.0	26

#	ARTICLE	IF	CITATIONS
19	Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab; the experience of the Australian compassionate access cohort. <i>Internal Medicine Journal</i> , 2015, 45, 1054-1065.	0.5	25
20	Establishing a Core Outcome Set for Autosomal Dominant Polycystic Kidney Disease: Report of the Standardized Outcomes in Nephrology Polycystic Kidney Disease (SONG-PKD) Consensus Workshop. <i>American Journal of Kidney Diseases</i> , 2021, 77, 255-263.	2.1	21
21	ADPedKD: A Global Online Platform on the Management of Children With ADPKD. <i>Kidney International Reports</i> , 2019, 4, 1271-1284.	0.4	20
22	Genomic diagnostics in polycystic kidney disease: an assessment of real-world use of whole-genome sequencing. <i>European Journal of Human Genetics</i> , 2021, 29, 760-770.	1.4	20
23	Renal genetics in Australia: Kidney medicine in the genomic age. <i>Nephrology</i> , 2019, 24, 279-286.	0.7	18
24	Prevalence of Fabry disease in dialysis patients: Western Australia Fabry disease screening study - the FORWARD study. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 10.	1.2	16
25	Cost-Effectiveness of Targeted Exome Analysis as a Diagnostic Test in Glomerular Diseases. <i>Kidney International Reports</i> , 2021, 6, 2850-2861.	0.4	15
26	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of Polycystic Liver Disease. <i>Seminars in Nephrology</i> , 2015, 35, 618-622.e5.	0.6	14
27	Genomics in the renal clinic - translating nephrogenetics for clinical practice. <i>Human Genomics</i> , 2015, 9, 13.	1.4	12
28	Fibrillary glomerulonephritis: An apparent familial form?. <i>Nephrology</i> , 2015, 20, 506-509.	0.7	12
29	The increasing rates of acute interstitial nephritis in Australia: a single centre case series. <i>BMC Nephrology</i> , 2017, 18, 329.	0.8	12
30	Kidney transplant recipient's perceptions of blood testing through microsampling and venepuncture. <i>Bioanalysis</i> , 2020, 12, 873-881.	0.6	12
31	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Management of Renal Stone Disease. <i>Seminars in Nephrology</i> , 2015, 35, 603-606.e3.	0.6	11
32	Australia and New Zealand renal gene panel testing in routine clinical practice of 542 families. <i>Npj Genomic Medicine</i> , 2021, 6, 20.	1.7	11
33	National and international kidney failure registries: characteristics, commonalities, and contrasts. <i>Kidney International</i> , 2022, 101, 23-35.	2.6	11
34	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Genetic Testing for Diagnosis. <i>Seminars in Nephrology</i> , 2015, 35, 545-549.e2.	0.6	10
35	Monoclonal gammopathy of renal significance triggering atypical haemolytic uraemic syndrome. <i>Nephrology</i> , 2017, 22, 15-17.	0.7	10
36	Birt-Hogg-Dubois Syndrome and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome: An Effective Multidisciplinary Approach to Hereditary Renal Cancer Predisposing Syndromes. <i>Frontiers in Oncology</i> , 2021, 11, 738822.	1.3	10

#	ARTICLE	IF	CITATIONS
37	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Pharmacological Management. <i>Seminars in Nephrology</i> , 2015, 35, 582-589.e17.	0.6	9
38	Isolated proteinuria due to CUBN homozygous mutation “ challenging the investigative paradigm. <i>BMC Nephrology</i> , 2019, 20, 330.	0.8	9
39	The Ckd. Qld fabRy Epidemiology (aCQuiRE) study protocol: identifying the prevalence of Fabry disease amongst patients with kidney disease in Queensland, Australia. <i>BMC Nephrology</i> , 2020, 21, 58.	0.8	9
40	Atypical HUS associated with severe, unexpected antibody-mediated rejection post kidney transplant. <i>Nephrology</i> , 2014, 19, 22-26.	0.7	8
41	A protocol for the identification and validation of novel genetic causes of kidney disease. <i>BMC Nephrology</i> , 2015, 16, 152.	0.8	8
42	Adult-Diagnosed Nonsyndromic Nephronophthisis in Australian Families Caused by Biallelic NPHP4 Variants. <i>American Journal of Kidney Diseases</i> , 2020, 76, 282-287.	2.1	8
43	Multiple Cerebral Aneurysms in an Adult With Autosomal Recessive Polycystic Kidney Disease. <i>Kidney International Reports</i> , 2021, 6, 219-223.	0.4	8
44	The prevalence of Fabry disease in a statewide chronic kidney disease cohort “ Outcomes of the aCQuiRE (Ckd.Qld fabRy Epidemiology) study. <i>BMC Nephrology</i> , 2022, 23, 169.	0.8	7
45	Ibuprofen-related renal tubular acidosis in pregnancy. <i>Obstetric Medicine</i> , 2011, 4, 122-124.	0.5	6
46	Sustained remission of systemic lupus erythematosus related calciphylaxis. <i>Lupus</i> , 2012, 21, 441-444.	0.8	6
47	Comprehensive evaluation of a prospective Australian patient cohort with suspected genetic kidney disease undergoing clinical genomic testing: a study protocol. <i>BMJ Open</i> , 2019, 9, e029541.	0.8	6
48	The Evolving Role of Diagnostic Genomics in Kidney Transplantation. <i>Kidney International Reports</i> , 2022, 7, 1758-1771.	0.4	6
49	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Genetics and Genetic Counseling. <i>Seminars in Nephrology</i> , 2015, 35, 550-556.e1.	0.6	5
50	Bleeding Complications of Percutaneous Kidney Biopsy: Does Gender Matter?. <i>Kidney360</i> , 2021, 2, 1308-1312.	0.9	5
51	A clinical approach to tubulopathies in children and young adults. <i>Pediatric Nephrology</i> , 2023, 38, 651-662.	0.9	5
52	Antenatally Diagnosed ADPKD. <i>Kidney International Reports</i> , 2018, 3, 1214-1217.	0.4	4
53	Precision Medicine Diagnostics for Rare Kidney Disease: Twitter as a Tool in Clinical Genomic Translation. <i>Kidney Medicine</i> , 2019, 1, 315-318.	1.0	4
54	DNAJB11-Related Atypical ADPKD in a Kidney Transplant Donor. <i>Kidney International Reports</i> , 2020, 5, 1363-1366.	0.4	4

#	ARTICLE	IF	CITATIONS
55	Clinical versus research genomics in kidney disease. <i>Nature Reviews Nephrology</i> , 2021, 17, 570-571.	4.1	4
56	Clinical Outcomes of People With Fabry Disease â€” ANZDATA Registry Study. <i>Kidney International Reports</i> , 2021, 6, 2481-2485.	0.4	4
57	The Heritability of Kidney Function Using an Older Australian Twin Population. <i>Kidney International Reports</i> , 2022, 7, 1819-1830.	0.4	4
58	Paraneoplastic immunoglobulin A nephropathy and associated focal segmental glomerulosclerosis in asymptomatic low volume B-cell lymphoma â€” a case report. <i>BMC Nephrology</i> , 2018, 19, 224.	0.8	3
59	ABO blood group relationships to kidney transplant recipient and graft outcomes. <i>PLoS ONE</i> , 2020, 15, e0236396.	1.1	3
60	Pharmacist-Led Education for Final Year Medical Students: A Pilot Study. <i>Frontiers in Medicine</i> , 2021, 8, 732054.	1.2	3
61	KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Psychosocial Care. <i>Seminars in Nephrology</i> , 2015, 35, 590-594.e5.	0.6	2
62	Pilot clinical and validation study of the PROPKD score in clinical practice amongst patients with Autosomal Dominant Polycystic Kidney Disease. <i>Nephrology</i> , 2020, 25, 274-275.	0.7	2
63	Protocol and establishment of a Queensland renal biopsy registry in Australia. <i>BMC Nephrology</i> , 2020, 21, 320.	0.8	2
64	Polypoid Change of the Glomerular Basement Membrane in a Child with Steroid Resistant Nephrotic Syndrome and ARHGAP24 Mutation: A Case Report. <i>The Open Urology &amp; Nephrology Journal</i> , 2016, 9, 88-93.	0.2	2
65	The HIDDEN Protocol: An Australian Prospective Cohort Study to Determine the Utility of Whole Genome Sequencing in Kidney Failure of Unknown Aetiology. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
66	<scp>NOS3</scp> as a potential modifier of <scp>ADPKD</scp> phenotypic variability: Progress towards an answer. <i>Nephrology</i> , 2014, 19, 733-734.	0.7	1
67	Recurrent atypical haemolytic uraemic syndrome post kidney transplant due to aCD46mutation in the setting ofSMARCAL1-mediated inherited kidney disease. <i>Nephrology</i> , 2017, 22, 11-14.	0.7	1
68	CFHR5 Nephropathy in a Greek-Cypriot Australian Family: Ancestry-Informed Precision Medicine. <i>Kidney International Reports</i> , 2018, 3, 1222-1228.	0.4	1
69	Proposed minimum information guideline for kidney diseaseâ€”research and clinical data reporting: a cross-sectional study. <i>BMJ Open</i> , 2019, 9, e029539.	0.8	1
70	Genetic Kidney Disease in Southern Tasmania. <i>Kidney International Reports</i> , 2020, 5, 534-537.	0.4	1
71	Clinical and Healthcare Utilization Outcomes of Parathyroidectomy in CKD and Dialysis Patients. <i>Kidney International Reports</i> , 2020, 5, 1086-1089.	0.4	1
72	Multi-phenotype genome-wide association studies of the Norfolk Island isolate implicate pleiotropic loci involved in chronic kidney disease. <i>Scientific Reports</i> , 2021, 11, 19425.	1.6	1

#	ARTICLE	IF	CITATIONS
73	An audit of electron microscopy in the diagnosis of focal segmental glomerulosclerosis: are current pathological techniques missing important abnormalities in the glomerular basement membrane?. F1000Research, 2019, 8, 1204.	0.8	1
74	Toward Transparency in Nephrology Research. Kidney International Reports, 2020, 5, 118-120.	0.4	0
75	Nephrology in Australia. , 2021, , 701-721.		0
76	Per-Treatment Post Hoc Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKD. Kidney International Reports, 2021, 6, 1032-1040.	0.4	0
77	MO1005ADPEDKD: A GLOBAL ONLINE PLATFORM TO EXPLORE THE CHILDHOOD PHENOTYPE OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE*. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
78	Monogenic Nephrolithiasisâ€”Collision of Phenotypes, Genotypes, and Phenocopies. Kidney International Reports, 2021, 6, 2737-2739.	0.4	0
79	Metformin for preventing the progression of chronic kidney disease. The Cochrane Library, 0, , .	1.5	0